Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

medicuspharma d.o.o., rokov perivoj 6/a, zagreb - dopaminklorid - koncentrat za otopinu za infuziju - 200 mg/10 ml - urbroj: 1 ampula koncentrata za otopinu za infuziju sadrži 200 mg dopaminklorida; 1 ml koncentrata za otopinu za infuziju sadrži 20 mg dopaminklorida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

medicuspharma d.o.o., rokov perivoj 6/a, zagreb, hrvatska - dopaminklorid - koncentrat za otopinu za infuziju - 50 mg/5 ml - urbroj: 1 ampula koncentrata za otopinu za infuziju sadrži 50 mg dopaminklorida 1 ml koncentrata za otopinu za infuziju sadrži 10 mg dopaminklorid

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

makpharm d.o.o., trnjanska cesta 37/1, zagreb, hrvatska - razagilintartarat - tableta - 1 mg - urbroj: svaka tableta sadrži 1 mg razagilina (u obliku tartarata)

Europska Unija - hrvatski - EMA (European Medicines Agency)

almirall s.a - tildrakizumab - psorijaza - imunosupresivima, inhibitori interleukina, - ilumetri indiciran za liječenje odraslih bolesnika s umjerenim do teškim plak psorijaza, koji su kandidati za sistemske terapije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

sandoz gmbh - pegfilgrastim - neutropenija - Иммуностимуляторы, - smanjenje duljine trajanja neutropenije i incidencije febrilne neutropenije u odraslih bolesnika liječenih citotoksičnom kemoterapijom zbog zloćudne bolesti (uz iznimku kronične mijeloične leukemije i mijelodisplastičnog sindroma).

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

zentiva pharma d.o.o. - telmisartan - film tableta - 40 mg/1 tableta - 1 film tableta sadrži: 40 mg telmisartan

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

zentiva pharma d.o.o. - telmisartan - film tableta - 80 mg/1 tableta - 1 film tableta sadrži: 80 mg telmisartan

Europska Unija - hrvatski - EMA (European Medicines Agency)

almirall, s.a. - tirbanibulin - keratosis, actinić - antibiotici i kemoterapeutici za dermatološku uporabu - klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (olsen grade 1) of the face or scalp in adults.

Europska Unija - hrvatski - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Europska Unija - hrvatski - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - ertapenem natrij - bakterijske infekcije - эртапенем - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 i 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. treba uzeti u obzir formalne preporuke za odgovarajuće korištenje antibakterijskih posrednika.